Stories
Best Biotechnology Startups In India
The biotechnology industry is one of the fastest growing segments in India. Valued at 11 billion USD in 2018, the Indian biotechnology industry is expected to touch the 100 billion USD mark by 2025, according to the Association of Biotechnology Led Enterprises (ABLE.) With more and more people choosing biotechnology as a career, there is ample chance of success in this field. We will be looking at the biotechnology startups which paved the way for the blooming biotechnology industry in India.
Best Biotechnology Startups In India
1)Biocon
This Bangalore based company is the largest biopharmaceutical company in India. Founded in 1978 with a budget of Rs. 10,000, Biocon started as a company selling the enzyme papain. In the 1990s, founder Kiran Mazumdar-Shaw decided to change the focus of the Company from selling enzymes to selling biopharmaceuticals. Subsequently, Shaw became one of the richest women in India. Today, Biocon sells insulin and monoclonal antibodies, among other products. The Company had an annual revenue of Rs. 4,709 crores in 2018.
2)Sea6 Energy
This startup was founded in 2010 by four IIT Madras graduates and works towards the development of scalable solutions to solve the problem of overconsumption of energy in India. The Company is developing techniques to convert photosynthetic biomass like plants and algae to fuels, in an effort to battle the increasing commercial use of energy in the Country. Incubated at the Centre for Cellular and Molecular Platforms (C-Camp) and funded by the Department of Biotechnology, the startup has patented techniques to facilitate large scale cultivation of selected sea plants.
3)Bharat Biotech
Headquartered at Hyderabad, this Company was founded in 1996 by an Indian scientist, Krishna Ella. One of the leading biopharmaceutical companies in India, Bharat Biotech was the first to develop and patent vaccines for the Zika virus, Zikavac, in the world. It is the first pharmaceutical company to develop a generic drug in India.
4)GANIT Labs
Founded in 2010 in Bangalore by Dr. Vinay Panda and Dr. Vijaya Chandru, Genomics Application and Information Technology Labs (GANIT Labs) is an independent government funded startup. GANIT Labs studies genomes related to oral cancer and helps in mapping their genes. It is also involved in creating analytical tools which effectively analyse and manage large scale genome data, mainly from genome sequencing of disease tissues like cancer.
5)MedGenomes
Founded by Sam Santosh in 2013, MedGenomes provides personalised genetic tests and medicines for a range of ailments like cancer, diabetes and neurological ailments. The Company has headquarters in the U.S.A., and India and claims to operate the largest next gen sequencing lab in southeast Asia. In 2017, the Company secured a whopping Rs. 192 crores in funding. In 2018, MedGenomes was given the MedTech Breakthrough Award for Biomedical Research.
With the growth of the biotechnology industry and a renewed interest of investors in it, the success story of these biotechnology startups will inspire many biotechnology entrepreneurs out there who are aspiring to start their own company one day.
A decade ago, the success of a startup was measured largely by its ability to raise capital. Today, a different metric is gaining importance: the ability to generate meaningful exits for investors. Large stake sales by early backers are becoming increasingly common, not because growth opportunities have disappeared, but because India’s startup ecosystem is entering a more mature phase where capital is expected to complete its full cycle from investment to returns.
This evolution is particularly significant for consumer brands that have successfully blended technology, retail, and strong brand-building. Companies that were once viewed as high-risk startup bets are now attracting institutional investors capable of absorbing large transactions. Such developments indicate that these businesses are no longer being valued solely on future potential; they are increasingly being assessed on operational performance, market leadership, and long-term profitability. In many ways, investor exits are becoming a validation of a company’s ability to create lasting enterprise value.
The broader implication extends beyond a single company or investor. Successful exits encourage more global capital to enter India’s startup ecosystem because they demonstrate that liquidity opportunities exist at scale. As more venture-backed companies approach public listings, secondary transactions, or strategic investments, the focus of founders and investors alike may shift from chasing headline valuations to building durable businesses. The next chapter of India’s startup journey will likely be defined not just by the creation of unicorns, but by the creation of companies capable of delivering sustained returns to all stakeholders.
Apple has unveiled the new MacBook Air with M5 chip, starting at $999 for 13-inch and $1,299 for 15-inch models. The MacBook Air M5 boasts a 2nm M5 chip with 12-core CPU, 18-core GPU, and 50 TOPS Neural Engine for seamless AI tasks like real-time translation and 8K editing. Up to 22 hours of battery life, Thunderbolt 5, and Wi-Fi 7 make it the ultimate ultraportable, now 10% thinner at 0.44 inches with fanless cooling.
Key MacBook Air M5 features include Liquid Retina XDR display (500 nits, nano-texture option), 12MP Center Stage camera, and six-speaker Spatial Audio. Colors like new Sky Blue join Midnight and Starlight. Pre-orders are live today, with macOS Sequoia 15.4 enhancing Apple Intelligence and iPhone Continuity for students, pros, and remote workers.
Why buy MacBook Air M5 now? It outpaces Snapdragon X Elite rivals with ecosystem magic and future-proof performance, eyeing top 2026 laptop sales. CEO Tim Cook calls it “more capable than ever.” Visit apple.com for M5 MacBook deals and specs.
Delhi NCR-based gaming startup Zupee has acquired Mumbai-based microdrama platform Vertical TV in a deal valued under INR 40 Cr. This move strengthens Zupee Studio, its short-video arm launched in September 2025, by integrating Vertical TV’s expertise in bite-sized dramas like romance and thrillers.
Facing challenges from India’s 2025 real-money gaming ban, Zupee valued at $1 Bn after raising $120 Mn has pivoted to non-gaming content, including recent layoffs of 40% of its workforce. The acquisition builds on its November 2025 purchase of Australian AI firm Nucanon for interactive storytelling, targeting its 200 Mn+ users with engaging, mobile-first formats.
This deal underscores the rising microdrama trend in India, helping Zupee diversify amid regulatory pressures and compete in the short-video space dominated by quick, shareable content for on-the-go audiences.
What Investor Exits Reveal About the New Age of Indian Startups
Healthy Snacking Is Emerging as India’s Next Consumer Growth Story
Salomon hiking shoe
April 24, 2026 at 10:49 am
I felt like this was written just for me.